Soft metal solid-state battery mimics biology, could drive EVs 500 miles per charge
Researchers at Georgia Tech have developed a new metal combination that could transform the future of solid-state batteries.
By blending lithium with a soft, surprising element, sodium, the team has found a way to reduce the pressure needed for these batteries to operate significantly.
This innovation could lead to lighter, longer-lasting power sources for everything from smartphones to electric vehicles.
The findings were published by the lab of Matthew McDowell, a professor in Georgia Tech's School of Mechanical Engineering and the School of Materials Science and Engineering.
His group has also filed for a patent on the breakthrough.
Solid-state batteries promise greater energy density and better safety than lithium-ion ones. They use a solid electrolyte instead of a flammable liquid, making them more stable.
However, they often require high pressure to work. The metal plates needed to apply that pressure are often heavier and bulkier than the battery itself.
'A solid-state battery usually requires metal plates to apply this high pressure, and those plates can be bigger than the battery itself,' McDowell said. 'This makes the battery too heavy and bulky to be effective.'
That challenge has kept solid-state batteries from reaching widespread use, despite years of research and hype.
The team, led by Georgia Tech research scientist Sun Geun Yoon, found that adding sodium to lithium changes the game.
Sodium is not active in the battery's electrochemical process, but its softness plays a key role.
'Adding sodium metal is the breakthrough,' McDowell said.
'It seems counterintuitive because sodium is not active in the battery system, but it's very soft, which helps improve the performance of the lithium.'
Sodium's softness is no exaggeration. In a controlled setting, someone could press a gloved finger into the metal and leave a mark.
When paired with lithium, it deforms easily under lower pressure, keeping better contact with the solid electrolyte. This improves overall battery performance.
To understand why sodium-lithium batteries perform better, the team turned to biology. Specifically, they used the concept of morphogenesis — the way biological structures evolve based on local conditions.
Morphogenesis is rare in materials science. But in this case, the interaction between sodium and lithium followed this pattern.
The researchers saw that sodium behaved like a deformable phase, adjusting to structural changes during battery use.
McDowell's team developed this concept under a project funded by the Defense Advanced Research Projects Agency (DARPA), alongside other universities.
The implications of this research are broad. It could lead to phone batteries that last far longer or electric vehicles capable of going 500 miles on a single charge.
The ability to reduce the pressure requirement without sacrificing energy capacity opens new possibilities for scaling solid-state batteries.
While challenges remain before commercialization, McDowell's group continues to test new materials.
Their goal is to make solid-state batteries more competitive with the lithium-ion standard. If successful, this shift could mark a major leap in battery technology.
The study is published in the journal Science.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
30 minutes ago
- Yahoo
Adolore BioTherapeutics Announces Publication Demonstrating Biosafety and Efficacy of Kv7 Activating rdHSV-CA8* Analgesic Gene Therapy for Chronic Pain via the Intra-Articular Route in Mice
Findings highlight the advantages of Adolore's approach for the delivery of proprietary gene therapy directly to specialized pain-sensing peripheral nerves (nociceptors) that mediates profound analgesia with the potential to address the great unmet need for non-opioid chronic pain therapies Data further supports the clinical-translational value of Adolore's proprietary non-opioid analgesics for treating chronic non-cancer pain These data support the Company's continuing efforts to progress with IND-enabling studies of ADB-102 gene therapy for the treatment of osteoarthritis (OA) chronic knee pain. DELRAY BEACH, FL / / June 15, 2025 / Adolore BioTherapeutics ("Adolore" or the "Company"), a biotechnology company focused on developing breakthrough opioid-free gene therapy treatments for chronic pain and neurological disorders, today announced the publication of its manuscript titled, "Biosafety and Efficacy of Kv7 Activating rdHSV-CA8* Analgesic Gene Therapy for Chronic Pain Via the Intra-Articular Route in Mice1," in the peer-reviewed journal, Molecular Therapy. Roy Clifford Levitt, MD, Clinical Professor at the University of Miami, Principal Investigator and Program Director of the NIH, NINDS, HEAL Award supporting ADB-102 development for the treatment of chronic knee pain due to OA, and Founder & Executive Chairman of Adolore BioTherapeutics, published biosafety and efficacy data from preclinical studies of Adolore's gene therapy expressing a human carbonic anhydrase-8 variant peptide (CA8*). In model systems, replication-defective, disease-free, herpes simplex virus (rdHSV) gene therapy expressing an analgesic carbonic anhydrase-8 (CA8*) peptide variant corrects somatosensory hyperexcitability by activating Kv7 voltage-gated potassium channels, produces profound, long-lasting analgesia and treats chronic pain from knee OA. In these studies, we provide the first non-Good Laboratory Practices (GLP) biosafety, efficacy, biodistribution, shedding, and histopathology examination of this rdHSV-CA8* via the intra-articular knee route of administration. Naive mice were examined for clinical safety, distribution of virus across all major tissues, knee histopathology, and analgesic efficacy. We observed no signs of persistent toxicity or histopathology, viral genomes remained where they were injected, and there was no evidence of shedding. Profound analgesia persisted for >6 months without functional impairments. These initial biosafety and efficacy data support further development of rdHSV-CA8* for treating chronic knee pain due to moderate-to-severe OA. Dr. Levitt, commented, "Kv7 voltage-gated potassium channel activators, like rdHSV-CA8* open these channels and hyperpolarize nociceptors making them less excitable to produce profound analgesia. Kv7 activators are well-known to produce potent non-opioid-based analgesia in many human chronic pain conditions. While Kv7 openers are no longer available due to off-target adverse events related to systemic administration, they have been successfully translated from animal models to human chronic pain conditions. Bolstered by our substantial body of published data, we continue to develop our innovative approach to address the significant serious unmet need for safe and effective locally acting pain therapies to replace opioids. Our preclinical data strongly support continued preclinical development toward an IND and clinical studies of ADB-102." The Company's lead development program for the treatment of chronic pain in knee osteoarthritis is fully funded by a UG3/UH3 grant awarded to the University of Miami by NIH/NINDS HEAL program to support all formal pre-clinical GLP/GMP/GCP development work through a first-in-human study of ADLR-1l01 in patients expected to commence in 2026. 1 Levitt et al., Biosafety and efficacy of Kv7 activating rdHSV-CA8* analgesic gene therapy for chronic pain via the intraarticular route in mice, Molecular Therapy (2025), About Carbonic Anhydrase-8 (CA8*) Gene Therapy CA8* (variants of naturally occurring human carbonic anhydrase-8 analgesic peptides) gene therapies are a novel class of neuronal calcium channel inhibitors that activate Kv7 voltage-gated potassium channels and are administered locally and long-acting. Oral small molecule pain therapeutics that activate Kv7 voltage-gated potassium channels demonstrated proven analgesic efficacy before they were removed from the market due to severe adverse events related to systemic exposure and their metabolism. CA8* gene therapy provides versatile dosing regimens and routes of administration, including intra-articular, intra-neuronal (nerve block), and intradermal injection. This non-opioid CA8* mechanism-of-action addresses neuropathic, inflammatory, and nociceptive pain, which applies to a broad range of chronic pain indications and neurological disorders. These conditions include osteoarthritis, lower back, and cancer pain; diabetes and other forms of peripheral neuropathy; as well as rare pain conditions such as erythromelalgia, a heritable chronic pain condition and epilepsy and hearing loss. About Adolore BioTherapeutics, Inc. Adolore BioTherapeutics, Inc., is a biotechnology company focused on developing novel therapies for treating chronic pain using a revolutionary intra-cellular replication-defective HSV (rdHSV) drug delivery platform that is disease-free, non-toxic, and permits localized peripheral nervous system delivery of proprietary biotherapeutics. This rdHSV gene therapy technology incorporates an established re-dosing strategy and an excellent safety profile. HSV vectors are known for their stability and prolonged gene expression, providing an excellent basis for the long- term treatment of chronic pain conditions and neurological disorders. Our best-in-class CA8* programs are long-acting, locally administered gene therapies that are opioid-free Disease-Modifying Anti-Pain therapies (DMAPs) designed to treat many forms of chronic pain, epilepsy and hearing loss. Leveraging its innovative gene therapy vectors expressing CA8* analgesic peptides (ADLR-1001), Adolore is currently advancing two preclinical development programs: ADB-101 for the treatment of patients' chronic pain caused by erythromelalgia, an orphan disease, and ADB-102, their lead program for the treatment of patients with chronic pain caused by knee OA. Based on substantial compelling preclinical data generated to date, the Company is progressing these programs toward IND filings and first-in-human clinical studies. Adolore has two additional programs: ADB-104 for Drug-Resistant Refractory Focal Epilepsy and ADB-105 for Acute Severe Hearing Loss. For more information, visit Forward-Looking Statements To the extent, this announcement contains information and statements that are not historical, they are considered forward-looking statements within the meaning of the federal securities laws. You can identify forward-looking statements by the use of the words "believe," "expect," "anticipate," "intend," "estimate," "project," "will," "should," "may," "plan," "intend," "assume" and other expressions which predict or indicate future events and trends and which do not relate to historical matters. You should not rely on forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, some of which are beyond the control of the Company. These risks and uncertainties include but are not limited to those associated with drug development. These risks, uncertainties, and other factors may cause the actual results, performance, or achievements of the Company to be materially different from the anticipated future results, performance, or achievements expressed or implied by the forward- looking statements. Investor Relations Contact Paul Barone (215)622-4542pbarone@ SOURCE: Adolore Biotherapeutics, Inc. View the original press release on ACCESS Newswire Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
38 minutes ago
- Yahoo
Scott Galloway has some choice metaphors to describe AI's impact on workers: 'I think of it as corporate Ozempic'
NYU professor Scott Galloway thinks a lot about AI. Galloway shared some vivid metaphors to describe how AI is changing the workplace. He said to think of it like "corporate Ozempic" or the "East German Stasi with WiFi." AI is changing the workplace fast, making it harder than ever for employees and their bosses to keep up. Scott Galloway, a New York University Stern School of Business professor and host of the podcast The Prof G Pod, shared some of the metaphors he's come up with to describe AI's impact on the workplace in a discussion with Microsoft Chief Scientist Jaime Teevan and Greg Shove, the CEO of Section, an AI education company. Here are some of Galloway's best metaphors: The leadership and boards of many companies are using AI to cut costs. In this scenario, Galloway said he thinks of AI as having some of the same properties as GLP-1s. The "dark side" of AI lies in how easily it can identify low performers, Galloway said, comparing it to East Germany's Cold War-era secret police, notorious for their widespread surveillance. For the top 10% of the US labor force, however, Galloway thinks AI is a boon. Read the original article on Business Insider
Yahoo
38 minutes ago
- Yahoo
NASA Satellite Glimpses Giant Volcano Peeking Above The Clouds of Mars
A spacecraft's-eye view over the landscapes of Mars has just given us a first-of-its-kind glimpse of the giant, ancient edifice known as Arsia Mons. The NASA satellite Odyssey captured the enormous equatorial volcano as its tip peeked above the morning clouds of water ice – a common feature at this time of the Martian year, when the red planet is at its furthest point from the Sun on its slightly elliptical orbit. Arsia Mons belongs to a volcanic complex known as the Tharsis Montes; three shield volcanoes very close together in the Tharsis region of Mars. Arsia Mons is the tallest of the three, standing at a towering height of nearly 20 kilometers (12 miles). That's dramatically higher than any mountain on Earth, where the tallest peak above sea level (Mount Everest) stands 8.85 kilometers high and the tallest mountain, Mauna Kea, rises 9 kilometers above the sea floor. It also has around 30 times more volume than Earth's largest volcano, Mauna Loa – and it's not even the biggest volcano on Mars. Its activity is thought to have lasted billions of years, peaking around 150 million years ago. Odyssey usually has its cameras pointed down toward the surface of Mars. To obtain the new panorama, it had to rotate 90 degrees so that its camera pointed at the horizon. This angle is worth the effort: it allows scientists to make out layers and clouds in the thin Martian sky to better understand its atmospheric dynamics and processes. Clouds form around Arsia Mons when expanding air rises up the slopes of the mountain, rapidly cooling, allowing ice crystals to form. At Mars's current position in its journey around the Sun, a belt of clouds forms around the equator known as the aphelion cloud belt. Curiosity captured this phenomenon from the surface several years ago; the new Odyssey panorama gives us a spectacular view from above. "We picked Arsia Mons hoping we would see the summit poke above the early morning clouds," says aerospace engineer Jonathon Hill of Arizona State University. "And it didn't disappoint." The Universe's Missing Black Holes May Have Been Located Mysteriously Magnetic Moon Rocks Might Have an Explosive Origin Story Fiery Orange Gems From The Moon Reveal Secrets of Its Violent Past